The main reason for the downturn in Moderna’s stock is a significant drop in the demand for its COVID-19 vaccine.

The Food and Drug Administration (FDA) has approved Moderna’s next-generation mRNA COVID-19 vaccine mNexspike ®.

The recent downturn in biotech has battered Massachusetts’ world-renowned sector, and the political climate has only made it ...

President Trump’s administration has slammed the brakes on development of messenger RNA (mRNA) vaccines, which proved their ...

A major revision to the schedule for COVID-19 vaccines comes on the heels of Sen. Ron Johnson’s, R-Wis., issuance of an ...

The U.S. Food and Drug Administration has approved a new lower-dose vaccine for active immunization against COVID-19 caused ...

A new COVID variant - NB 1.8.1 - is creeping across California; here are the symptoms to watch for, and vaccinations you'll ...

Moderna (NASDAQ: MRNA) stock represented the ticket to an investing win. The company brought its coronavirus vaccine from ...

Major vaccine policy changes could be on the horizon as the HHS removes key advisors. Click for my thoughts on what this may ...

In a crucial development, the FDA has approved Moderna's new COVID-19 vaccine designed specifically for high-risk Americans.

The Trump administration is waging war against mRNA vaccines despite President Donald Trump having called them the “gold standard” when his admin rolled out the COVID shots […] ...

A vaccine expert assured Filipinos on Wednesday that all vaccines are safe after the United States Food and Drug ...